Table 2. Clinico-pathological Features of the 2 subgroups who underwent TACE.
| Variable | Lipiodol accumulation | ||
|---|---|---|---|
| Low (n = 50) | High (n = 27) | P Value | |
| Age(years) | 48.9 ± 9.4 | 51.4 ± 9.6 | 0.270 |
| Gender(n),Male:Female | 45/5 | 24/3 | 0.879 |
| AFP(μg/L), < 20: ≥ 20 | 8/42 | 3/24 | 0.440 |
| CEA(μg/L) | 4.4 ± 13.8 | 3.3 ± 4.1 | 0.705 |
| AST(IU/L) | 76.0 ± 40.1 | 85.5 ± 47.3 | 0.362 |
| ALT(IU/L) | 62.1 ± 44.3 | 59.1 ± 30.3 | 0.754 |
| Total bilirubin(μmol/L) | 19.4 ± 9.2 | 19.4 ± 9.4 | 0.931 |
| HBsAg(n),Positive:Negative | 44/6 | 23/4 | 0.703 |
| Tumor number(n), Single:Multiple | 30/20 | 14/13 | 0.604 |
| Tumor diameter(cm) | 9.1 ± 3.3 | 9.0 ± 3.5 | 0.931 |
| TACE sessions, 1: > 1 | 25/25 | 22/5 | 0.014 |
| Classification of PVTT (n) | 0.171 | ||
| Type I | 9 | 11 | |
| Type II | 21 | 10 | |
| Type III | 14 | 6 | |
| Type IV | 6 | 0 | |